Table 3 Positivity for ER, PR, p53, p21, p63, and KI-67 in HUT areas of reduction aesthetic mammaplasty specimens (HUT-ARM), HUT of mammaplasty contralateral to breast cancer (HUT-MCC); HUT adjacent to invasive mammary carcinoma (HUT-IMC), and in invasive mammary carcinoma (IMC)
Antibody | HUT-ARM n (%) | HUT-MCC n (%) | HUT-IMC n (%) | IMC n (%) |
|---|---|---|---|---|
RE | 33 (97.1) | 13 (86.7) | 32 (94.1) | 18 (52.9) |
RP | 34 (100) | 12 (80,0) | 33 (97.1) | 18 (52.9) |
p53 | 0 (0) | 0 (0) | 0 (0) | 19 (55.9) |
p21 | 0 (0) | 0 (0) | N*- 2 (5.9) | N*- 19 (55.9) |
| Â | Â | Â | C*- 6 (17.6) | C*- 8 (23.5) |
p63 | 34 (100) | 15 (100) | 34 (100) | 3 (8.8) |
Ki-67 ** | L- 20 (58.8) | L- 4 (26.7) | L- 22 (64.7) | L- 9 (26.5) |
| Â | I- 2 (5.9) | I- 2 (13.3) | I- 5 (14.7) | I- 17 (50) |
| Â | Â | Â | Â | H- 8 (23.5) |